EPEleni Patrikiou

Eleni Patrikiou

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eleni Patrikiou has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cancer-associated myositis: a single-centre 20-year experience

    by Vasiliki Syrmou, Theodora Simopoulou, Eleni Patrikiou, Christos Liaskos, Ioannis Alexiou, Lazaros I. Sakkas, Christina G. Katsiari, Dimitrios P. Bogdanos

    Background: Malignancy identified around the onset of idiopathic inflammatory myopathy (IIM) is referred to as cancer-associated myositis (CAM), but population-specific data remain relatively limited. Aim: To describe the prevalence, clinical features, and risk factors for CAM over a 20-year period in a single tertiary centre in Greece. Methods: A retrospective analysis was conducted on 113 IIM cases treated between 2001 and 2024 in our department, which is a referral centre for rheumatic disease in Central Greece. Medical records were evaluated for demographics, clinical characteristics, autoantibody profile, and comorbidities. CAM was defined as cases of myositis complicated by the onset or recurrence of cancer within 3 years before or after the diagnosis of myositis. Results: CAM was identified in 25 (22.1%) patients. Older age and dermatomyositis subtype were associated with CAM. Anti-TIF1γ autoantibody confers significantly higher risk (OR 6.9, p < 0.001), while anti-Jo1 lowers risk (OR 0.13, p = 0.022). Gottron’s papules and Holster sign were significantly associated with CAM. Raynaud’s phenomenon, interstitial lung disease and the non-interstitial pneumonia pattern appeared protective. Hypothyroidism was less common, while myocardial infarction was more frequent in CAM. Breast, ovarian, and lung cancers were the most common malignancies identified. In most cases, malignancy was asymptomatic (85%) and was determined upon screening. Survival was significantly lower in CAM p < 0.001 with the survival rate dropping down to 45% at 31 months vs 95.9% in non-CAM. Median survival was 21 months in CAM cases (1–79 months). Conclusion: CAM accounts for a substantial proportion of IIM cases. Anti-TIF1γ positivity, older age, absence of Raynaud’s phenomenon, and absence of ILD may serve as clinical flags in our cohort. Comprehensive cancer screening, including GI endoscopy, remains vital in the initial assessment and follow-up, primarily upon relapses and lack of remission. Key Points • Population-based studies on cancer-associated myopathy have established a clear, strong link between idiopathic inflammatory myopathies (IIM) and malignancy, often termed cancer-associated myositis (CAM) .• This study examines CAM prevalence, features, and risk factors over 20 years at a Greek tertiary center .• CAM was present in 22% of IIM patients, mostly asymptomatic (85%), identified through screening; breast, ovarian, and lung cancers were the common malignancies .• Akin to previous studies, anti-TIF1γ autoantibody confers a significantly higher risk, while anti-Jo1 lowers risk .


  • Open Access

    Role of Anti-EBNA-1 Antibodies in Psoriasis: A Seroprevalence Study

    by Eleni Patrikiou, Niki Davari, Athanasios Gkoutzourelas, Christos Liaskos, Dimitrios P. Bogdanos, Efterpi Zafiriou, Niki Ntavari

    Environmental triggers, particularly viral infections such as Epstein-Barr virus (EBV), may significantly contribute to the induction or exacerbation of psoriasis (Ps). EBV persists lifelong and is linked to several autoimmune diseases. Nuclear antigen 1 (EBNA-1) helps maintain latency and is a key immune target. Objective: This study aimed to investigate the potential association between EBV infection, specifically the humoral immune response to EBNA-1, and psoriasis by comparing seroprevalence and antibody levels in psoriatic patients versus healthy controls. Methods: A case-control study was conducted involving 23 patients with psoriasis (Ps) and 22 healthy controls (HC). Serum samples were analyzed for the presence of anti-EBNA-1 IgG antibodies using a standard enzyme-linked immunosorbent assay (ELISA). Seropositivity rates were compared using Fisher’s Exact Test, and quantitative antibody levels, expressed as mean ± standard deviation, were compared using an appropriate parametric test. Results: A significantly higher proportion of psoriatic patients were seropositive for anti-EBNA-1 antibodies than healthy controls (95.7% vs. 59.1%, p = 0.004). However, among seropositive individuals, the mean quantitative antibody levels did not differ significantly between the two groups (Ps: 63 ± 25.7 vs. HC: 75.6 ± 31.6, p = ns). Conclusion: Anti-EBNA-1 EBV antibodies are more prevalent in psoriasis compared to healthy controls, and further research is warranted to elucidate the mechanistic role of that viral antigen as a potential contributor to disease-related immune inflammation.

  • Open Access

    Fibromyalgia and menopause: Friends with benefits?

    by Arriana Gkouvi, Katerina-Maria Kontouli, Eleni C. Pardali, Eleni Patrikiou, Irene Lambrinoudaki, Dimitrios G. Goulis, Dimitrios P. Bogdanos, Maria G. Grammatikopoulou


  • Open Access

    Janus kinase inhibitors in giant cell arteritis: unmet needs and new challenges

    by Arriana Gkouvi, Eleni Patrikiou, Maria G. Grammatikopoulou, Dimitrios P. Bogdanos


  • Open Access

    Screening and diagnosis of sarcopenia in rheumatic and musculoskeletal diseases: findings from a cross-sectional study

    by Eleni C. Pardali, Katerina-Maria Kontouli, Arriana Gkouvi, Irene A. Tsakmaki, Eleni Patrikiou, Maria Karapli, Christos Liaskos, Nektarios Marios Liapis, Vasiliki Syrmou, Ioannis Alexiou, et al.

    Sarcopenia is characterized by loss of muscle mass and reduced muscle function, presenting various adverse events, especially when inflammation is present. The present study aimed to determine the prevalence of sarcopenia and sarcopenic obesity among patients with rheumatic and musculoskeletal diseases (RMDs) and identify the risk for sarcopenia using two screening tools the Strength, assistance with walking, rising from a chair, climbing stairs, and falls (SARC-F) and the Mini Sarcopenia Risk Assessment (MSRA). In this single-center cross-sectional study, 220 consecutive patients visiting the Department of Rheumatology and Clinical Immunology at the University General Hospital of Larissa were interviewed. The EWGSOP criteria were used for the diagnosis of sarcopenia, while sensitivity, specificity, positive predictive values, number needed to screen, and positive and negative likelihood ratios were used to validate the diagnostic validity of the SARC-F and the MSRA. Univariate and multivariate logistic regression analyses were also applied to model the relationship between sarcopenia and other variables. In the total sample, 15.9% of patients were diagnosed with sarcopenia and one patient with sarcopenic obesity. The SARC-F (sensitivity 22.2%, specificity 75.6%), the 5-item (sensitivity 88.9%, specificity 18.9%), and the 7-item MSRA (sensitivity 91.7%, specificity 9.2%) presented poor clinical performance when used for screening alone. Univariate logistic regression analyses showed that underweight status, systemic sclerosis and appetite loss are strong contributors to sarcopenia diagnosis. Sarcopenia is prevalent among RMDs, and screening is essential within RMD clinics. None of the screening tools (SARC-F and MSRA) can stand alone in assessing sarcopenia in patients with RMDs. More research is required to understand sarcopenia in RMDs and validate the wide-using screening tools.


  • Investigating the link between Helicobacter pylori infection and psoriatic disease: an immunological study

    by Eleni Patrikiou, George Efthymiou, Christos Liaskos, Niki Ntavari, Thomas Scheper, Wolfgang Meyer, Theodora Simopoulou, Efthymios Dardiotis, Aggeliki-Victoria Roussaki-Schulze, Efterpi Zafiriou, et al.

    Helicobacter pylori (Hp) has been postulated as an infectious trigger of psoriatic disease, namely psoriasis (Ps) and psoriatic arthritis (PsA), but meticulous antibody (ab) reactivity against all dominant and subdominant Hp antigens in demographically matched PsA and Ps patients and healthy controls has not been performed so far. IgG anti-Hp ab testing was performed by combining immunoblotting and line assays in 263 serum samples from 89 patients with PsA, 114 patients with Ps, and 60 demographically matched healthy controls (HCs). Anti-Hp positivity did not differ between PsA, Ps, and HCs (P > 0.05 for all comparisons). In PsA, anti-p75, anti-p67-FSH, anti-p66-UreB, anti-p54-flagellin, anti-p41, and anti-p30-OMP abs were more frequent in patients compared to HCs (P < 0.001, P = 0.028, P = 0.010, P = 0.003, P = 0.012, P = 0.020 respectively). In Ps, anti-p66-UreB and anti-p54-flagellin abs were more frequent than HC (P = 0.015 and P = 0.011, respectively), while anti-p50 abs were less frequent than HCs (P = 0.008). Anti-p75, anti-p67-FSH, anti-p50, anti-p41, anti-p30-OMP, anti-p29 = UreA and anti-p26 ab levels were higher in PsA compared to Ps (P = 0.012, P = 0.036, P < 0.001, P = 0.021, P = 0.002, P = 0.006 and P = 0.021 respectively). DAS28 scores were positively correlated with anti-p19 ab levels (r = 0.349, P = 0.050) in PsA patients by linear regression analysis. No other significant clinical association with anti-Hp responses was noted in patients with PsA and Ps. Our results demonstrate that several antigen-specific anti-Hp abs are more frequent in patients with psoriatic disease; however, negative correlations also exist, raising doubts about whether Hp is immunologically linked to psoriatic disease.

  • Delphinidin diminishes in vitro interferon-γ and interleukin-17 producing cells in patients with psoriatic disease

    by Sotirios G. Tsiogkas, Αthanasios Mavropoulos, Dimitrios N. Skyvalidas, Eleni Patrikiou, Niki Ntavari, Athina Ioanna Daponte, Maria G. Grammatikopoulou, Efthimios Dardiotis, Aggeliki-Victoria Roussaki-Schulze, Lazaros I. Sakkas, et al.

    The anthocyanidin delphinidin reduces psoriasiform lesions and inflammatory mediators in human cell culture systems. Its role in psoriatic disease has not yet been investigated. We assessed delphinidin’s in vitro immunomodulatory effect on ex vivo stimulated peripheral blood mononuclear cells (PBMCs) from 50 individuals [26 with psoriasis, 10 with psoriatic arthritis (PsA) and 14 healthy controls (HCs)]. Cells were either left untreated or stimulated with PMA plus ionomycin in the presence or absence of delphinidin. Intracellular production of interferon-γ (IFNγ), interleukin-17A (IL-17A), and interleukin-10 (IL-10) was measured flow cytometrically. Delphinidin dose-dependently reduced IFNγ+ T cells from patients and HCs. The mean IFNγ decrease in CD4+ T subpopulations was 42.5 ± 28% for psoriasis patients, 51.8 ± 21.5% for PsA patients and 49 ± 17% for HCs (p < 0.001 for all). Similarly, IFNγ reduction in CD8+ T cells was 34 ± 21.6% for psoriasis patients, 47.1 ± 22.8% for PsA and 44.8 ± 14.3% for HCs (P < 0.001 for all). An inhibitory effect of delphinidin was also noted in IFNγ producing NKs and NKTs from psoriasis individuals. Delphinidin also significantly decreased IL-17+ CD4+ T cells in all tested subjects, with marginal effect on the increase of IL-10-producing T regulatory subsets. In conclusion, delphinidin exerts a profound in vitro anti-inflammatory effect in psoriasis and psoriatic arthritis by inhibiting IFNγ+ innate and adaptive cells and T helper (Th) 17 cells. If this effect is also exerted in vivo, delphinidin may be regarded as a nutraceutical with immunosuppressive potential.


  • Open Access

    Τhe Greek Variant in APP Gene: The Phenotypic Spectrum of APP Mutations

    by Stefania Kalampokini, Despoina Georgouli, Eleni Patrikiou, Antonios Provatas, Varvara Valotassiou, Panagiotis Georgoulias, Cleanthe Spanaki, Georgios M. Hadjigeorgiou, Georgia Xiromerisiou

    Mutations in the gene encoding amyloid precursor protein (APP) cause autosomal dominant inherited Alzheimer’s disease (AD). We present a case of a 68-year-old female who presented with epileptic seizures, neuropsychiatric symptoms and progressive memory decline and was found to carry a novel APP variant, c.2062T>G pLeu688Val. A comprehensive literature review of all reported cases of AD due to APP mutations was performed in PubMed and Web of Science databases. We reviewed 98 studies with a total of 385 cases. The mean age of disease onset was 51.3 ± 8.3 (31–80 years). Mutations were most often located in exons 17 (80.8%) and 16 (12.2%). The most common symptoms were dementia, visuospatial symptoms, aphasia, epilepsy and psychiatric symptoms. Mutations in the β-amyloid region, and specifically exon 17, were associated with high pathogenicity and a younger age of disease onset. We describe the second reported APP mutation in the Greek population. APP mutations may act variably on disease expression and their phenotype is heterogeneous.